Carvykti (ciltacabtagene autoleucel)

Multiple myeloma (MM) in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and who are refractory to their last treatment.